Best ACE Inhibitor or ARB for Proteinuria

Evidence Supporting Equivalence

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend initiating either an ACE inhibitor or an ARB in patients with diabetes, hypertension, and albuminuria, with titration to the highest approved tolerated dose 2
The Kidney Disease Outcomes Quality Initiative (KDOQI) 2007 guidelines concluded that no claims of superiority between ACE inhibitors and ARBs can be made in type 1 diabetes, and a head-to-head comparison in type 2 diabetes suggested clinical equivalency 1

Titrate to the maximum tolerated dose, not just to blood pressure control, with the goal of proteinuria reduction to <1 g/day 2, 3
Accept up to 30% increase in serum creatinine after initiation, as this is hemodynamic and expected, not a reason to stop therapy, and continue treatment unless creatinine rises >30% or refractory hyperkalemia develops 2, 3

Dietary sodium restriction to <2.0 g/day is mandatory, as it enhances the antiproteinuric effect of both ACE inhibitors and ARBs synergistically 3, 4, 5
Monitor serum creatinine and potassium within 2-4 weeks after starting or increasing the dose, and hyperkalemia can often be managed with dietary potassium restriction, diuretics, or potassium binders rather than stopping the ACE inhibitor/ARB 2
Counsel patients to hold ACE inhibitor/ARB therapy during intercurrent illnesses with volume depletion risk to prevent acute kidney injury 4, 5

Target systolic blood pressure <120 mmHg using standardized office measurement in most patients with proteinuria, as lower targets provide additional renoprotection beyond proteinuria reduction alone 3, 4